At the Cantor Fitzgerald Global Healthcare Conference held on September 10, 2026, BioMarin Pharmaceutical Inc. (BMRN) detailed its evolving growth strategy, emphasizing the expansion of its pipeline beyond its flagship product, VOXZOGO. The company, valued at $12.5 billion with a current stock price of $65.80, reported a 20% year-over-year increase in its most recent quarterly revenue portfolio. With a P/E ratio of 171.5 and a fair value estimate of $84.46, BioMarin’s market outlook remains robust, though its valuation remains elevated relative to peers in the biotech sector.
VOXZOGO, BioMarin’s approved treatment for hypochondroplasia, continues to drive growth, with full-year 2026 guidance raised to $1.0 billion to $1.05 billion. The drug accounts for 75% of its revenue outside the U.S. and is marketed in 55 countries, underscoring its international appeal. The company also secured a 20% royalty on net U.S. sales and 18% royalties on net sales in the EU, South Korea, and Brazil from Ascendis Pharma following a settlement agreement. Despite a rival product’s launch in February 2024, VOXZOGO retained 90% of its patient base, with annualized growth velocity improvements of 2.33 centimeters. U.S. commercialization is set for 2025, with full FDA approval scheduled for February 28, 2025, coinciding with Rare Disease Day.
Beyond VOXZOGO, BioMarin’s pipeline includes several high-potential candidates. BMN 333, a next-generation long-acting CNP molecule, is advancing through Phase II/III trials, enrolling 40 patients across seven countries. The study aims for a 50% improvement in annualized growth velocity (2.25 centimeters) by 2027, with phase I results showing up to 13-fold higher exposure and extended half-life compared to existing treatments.
The company’s acquisition of Amicus Therapeutics in 2024 has also accelerated its pipeline. BMN 820 (DMX-200), developed for focal segmental glomerulosclerosis, is expected to read out from its Phase III study in 2028. Additionally, BioMarin acquired ALE-001 from Alesta Therapeutics for hypophosphatasia, a rare disease, in late August 2026. The deal underscores BioMarin’s strategy to expand its rare disease portfolio, with potential peak revenue projections of $1.4 billion for Galafold (Fabry disease) and $1.2 billion for POMBILITI/OPFOLDA (PomUp) in the mid-to-late 2030s, each with 10% to 20% CAGR. The company plans to expand Galafold into 10 additional countries and POMBILITI into over 20 countries, further diversifying its revenue streams.
Amicus’s integration is expected to deliver $220 million in annual synergies by 2028, primarily through G&A savings, while also contributing to non-GAAP EPS accretion in 2027. The company’s broader strategy reflects a commitment to leveraging its rare disease expertise while expanding into new therapeutic areas, positioning BioMarin as a dynamic player in the biopharmaceutical sector.
